GABA

Role in the CNS

GABA is the primary inhibitory neurotransmitter of the CNS, counterbalancing the excitatory action of glutamate. Roughly 20–40% of all synapses in the brain are GABAergic. GABA-releasing interneurons serve as the "brakes" of neural circuits — regulating the timing and synchronization of neuronal activity, preventing runaway excitation, and setting the threshold for all other neurotransmitter systems.

GABA-A Receptors

GABA-A receptors are pentameric ligand-gated ion channels assembled from a family of subunits (α1–6, β1–3, γ1–3, δ, ε, π, θ, ρ). The subunit composition determines the receptor's pharmacological properties, sensitivity, and localization:

• α1-containing receptors — the most prevalent subtype, mediating sedation, anticonvulsant effects, and amnesia. Principal target of classical benzodiazepines (diazepam, alprazolam)
• α2/α3-containing receptors — mediate anxiolytic and muscle-relaxant effects; target of selective "non-sedating" benzodiazepines under development
• α5-containing receptors — found at extrasynaptic sites in the hippocampus; regulate memory consolidation and spatial learning
• δ-subunit-containing receptors — extrasynaptic, tonically activated by ambient GABA, particularly sensitive to neurosteroids and low-dose ethanol

The GABA-A complex contains multiple distinct allosteric binding sites beyond the orthosteric GABA binding site:

• Benzodiazepine site — the BZD site, between the α and γ subunits; positive allosteric modulators (PAMs) here increase chloride current frequency without opening the channel in the absence of GABA
• Barbiturate/anesthetic site — transmembrane domain; barbiturates and anesthetics increase both frequency and duration of channel opening; at high doses they can open the channel directly (no GABA required — explaining barbiturate lethality vs. benzodiazepine safety)
• Neurosteroid sites — at least two; endogenous neurosteroids (allopregnanolone, THDOC) and exogenous agents (etomidate, SAGE-217) bind here
• Alcohol site — δ-subunit extrasynaptic receptors are particularly ethanol-sensitive at low doses; multiple transmembrane sites contribute at higher concentrations

GABA-B Receptors

GABA-B receptors are heterodimeric GPCRs (GABA-B1 + GABA-B2 subunits) that signal via Gi/o proteins, inhibiting adenylyl cyclase and modulating potassium and calcium channels. They are located both postsynaptically (producing slow IPSPs) and presynaptically (as autoreceptors, reducing GABA release, and heteroreceptors, reducing glutamate/dopamine release). Baclofen is the prototypical GABA-B agonist, used clinically for spasticity and off-label for alcohol use disorder.

Synthesis and Metabolism

GABA is synthesized from glutamate by glutamic acid decarboxylase (GAD), a pyridoxal phosphate (B6)-dependent enzyme expressed in two isoforms: GAD65 and GAD67. After release and receptor activation, GABA is cleared from the synapse primarily by reuptake via sodium-dependent GABA transporters (GAT-1 through GAT-4). Intracellularly, GABA is metabolized by GABA transaminase (GABA-T) to succinic semialdehyde, entering the tricarboxylic acid cycle. The anticonvulsant vigabatrin inhibits GABA-T, increasing synaptic GABA levels.

Relationship to Other Neurotransmitters

The glutamate/GABA balance is the master excitatory/inhibitory dial of the CNS. Disruption of this balance is implicated in epilepsy (excess excitation), anxiety disorders (insufficient inhibition), and the pharmacology of withdrawal states. Chronic GABAergic drug exposure causes receptor downregulation and subunit recomposition, forming the neurological basis of benzodiazepine and alcohol tolerance and dependence.

Discovery of GABA as a Neurotransmitter

GABA was first identified in the mammalian brain in 1950 by Eugene Roberts and Sam Frankel (and independently by Jorge Awapara), who detected it using paper chromatography. The early finding was unexpected — it was unclear what GABA did there. At the time, glutamate (GABA's precursor) was already under investigation as an excitatory amino acid, but GABA's inhibitory function was not yet understood.

The crucial demonstration that GABA acts as an inhibitory neurotransmitter came from electrophysiological studies in the late 1950s and early 1960s. Kuffler and Edwards showed in 1958 that GABA mimicked the inhibitory postsynaptic potential in crustacean stretch receptors. Later work by Krnjević and Schwartz in the mammalian cortex confirmed GABA's role as the dominant inhibitory neurotransmitter in the vertebrate brain.

GABA-A Receptor Characterization

The GABA-A receptor was first isolated and characterized biochemically in the early 1980s. The receptor's multi-subunit structure and the existence of multiple pharmacological binding sites became clear through the work of multiple groups including those of Eric Barnard and Werner Sieghart. The cloning of individual GABA-A subunits through the late 1980s and 1990s revealed the enormous diversity of receptor subtypes — now understood to comprise at least 19 different subunit genes — and explained the complex pharmacology of this receptor class.

Benzodiazepine Discovery and the GABA Connection

Chlordiazepoxide (Librium) was discovered by Leo Sternbach at Hoffmann-La Roche in 1955 (first synthesized as a potential dye intermediate) and found to have anxiolytic properties in animal testing. Diazepam (Valium) followed in 1963. Their commercial success was enormous — by the 1970s, benzodiazepines were the most prescribed drugs in the world. However, the mechanism of action was not understood until 1977, when Braestrup and Squires (and independently, Möhler and Okada) identified the benzodiazepine binding site on the GABA-A receptor, directly linking the drug's action to the GABAergic system.

GABA-B Receptor and Baclofen

The GABA-B receptor was pharmacologically identified in the early 1980s by Norman Bowery, who observed that baclofen (a GABA analogue developed for spasticity) had effects that were not blocked by GABA-A antagonists. GABA-B receptors were formally characterized as a distinct class and the receptor was cloned in 1997. Baclofen remains the primary GABA-B agonist in clinical use; its potential role in alcohol use disorder — based on self-report from French cardiologist Olivier Ameisen, who treated his own alcoholism with high-dose baclofen — has driven renewed clinical interest.

Current Research

Contemporary GABA research focuses on subtype-selective GABA-A modulators — attempting to separate anxiolytic effects (α2/α3-mediated) from sedation and dependence (α1-mediated). Allopregnanolone (brexanolone), a neurosteroid GABA-A modulator, was FDA-approved in 2019 for postpartum depression — the first drug specifically approved for that indication. Research into the role of altered GABAergic signaling in autism spectrum disorder, schizophrenia, and fragile X syndrome remains highly active.